Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab and Bendamustine in CLL
NCT01520922Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2012
- Primary completion
- Feb 2013
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of ofatumumab in chronic lymphocytic leukemia (CLL), sponsored by Novartis. Started Mar 2012; status: completed.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01520922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01520922.